Skip to content

A study to compare the efficacy of artificial cornea in restoring vision in comparison to human cornea transplant.

A Clinical Trial to evaluate the safety and effectiveness of the RHCIII-MPC biosynthetic cornea in patients requiring deep anterior lamerllar keratoplasty

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/10/005114
Enrollment
10
Registered
2014-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Biosynthetic RHC III Biosynthetic Cornea: Anterior lamellar Keratoplasty Control Intervention1: Human donar Cornea: Anterior lamellar Keratoplasty

Sponsors

Dr May Griffith
Lead Sponsor
Dr Virender S Sangwan
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects must sign and be given a copy of the written Informed Consent form. 2. Subjects with CDVA 20/200 or worse as a result of corneal scar due to injury or infection in the operative eye or from progressive keratoconus or Dystrophies or any other causes requiring DALK. 3. Subjects must be>=18 and 4. Subjects must be willing and able to return for scheduled follow-up examinations for 12 months after surgery.

Exclusion criteria

Exclusion criteria: 1.Subjects with severe or life-threatening systemic disease. 2.Subjects with uncontrolled hypertension. 3. Subjects with autoimmune disease. 4. Subjects with uncontrolled diabetes or insulin-dependent diabetes. 5. Subjects with an ocular infection. 6. Subjects with any anterior segment pathology (chronic uveitis, iritis, iridocyclitis, rubeosis, iritis, corneal dystrophy, pseudoexfoliation, etc. in the operative eye. 7. Subjects with glaucoma in either eye. 8.Subjects with previous retinal detachment or retinal pathology in the operative eye. 9.Subjects with congenital bilateral cataracts. 10.Subjects with marked microphthalmos or aniridia in either eye. 11.Subjects who have had previous ocular surgery in the operative eye, except pterygium or strabismus surgeries which may be allowed based on clinical evaluation. 12.Subjects who are or lactating or who plan to become pregnant over the course of the clinical investigation. 13.Subjects with any other serious ocular pathology,serious ocular complications at the time of corneal transplant underlying serious medical conditions,based on the Investigator medical judgement.

Design outcomes

Primary

MeasureTime frame
Visual Acuity Clarity of Implant Timepoint: Preoperative Evaluation (Day -60 to Day -1) Operative Evaluation (Day 0) Day 1(24 to 36 hours post-op) Week 1 (5 to 9 days post-op) Month 1(3 to 5 weeks post-op) Month 6(21 to 26 weeks post-op) Month 9 Month 12

Secondary

MeasureTime frame
1. Manifest refraction Preoperative 2. Uncorrected visual acuity (ETDRS) 3. Distance-corrected visual acuity without add (ETDRS) 4. Distance-corrected near visual acuity with add (ETDRS) 5. Slit lamp examination 6. Central keratometry 7. Computerized corneal topography 8. Specular microscopy of the corneal endothelium on both eyes 9. Central applanation intraocular pressure 10. Dilated fundus examination 11. Anterior segment OCT 12. Subject questionnaire Timepoint: Preoperative Evaluation (Day -60 to Day -1) Operative Evaluation (Day 0) Day 1 (24 to 36 hours post-op) Week 1(5 to 9 days post-op) Month 1 (3 to 5 weeks post-op) Month 6 (21 to 26 weeks post-op) Month 9 Month 12

Countries

India

Contacts

Public ContactDr Virender S Sangwan

L V Prasad Eye Institute

vsangwan@lvpei.org040-30612632

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026